iSpecimen Inc. (ISPC): Entry into a Material Definitive Agreement
iSpecimen Inc. (ISPC) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. On November 6, 2026, iSpecimen Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain accredited investors (the “Purchasers”) for the issuance and sale, in a priva
- Instrument
- Series D Convertible Preferred Stock
- Gross proceeds
- $400,000
- Shares
- 500 shares
- Price per share
- $800 per share
- Use of proceeds
- working capital and general corporate purposes
Facts are quoted from the filing text and checked against it.
How this was made
The 30-second read
Why it matters
The infusion of $400k provides working capital but adds a convertible security that may dilute existing shareholders and affect price dynamics.
Market read
A micro‑cap capital raise with limited market impact; primarily relevant to current shareholders and short‑term traders.
What to watch
Potential future conversion of preferred shares could increase share count significantly if the stock price rises.
Background
SEC Form 8‑K filed on Nov 9, 2026 discloses iSpecimen's private placement of Series D convertible preferred stock.
Ticker impact
iSpecimen Inc. entered a securities purchase agreement issuing 500 Series D convertible preferred shares for $400,000 gross proceeds.
likely modest downward pressure as dilution offsets the capital infusion, with upside potential if conversion terms become favorable.
The raise is modest ($400k) for a micro‑cap, so market impact will be limited; however, the convertible feature and redemption rights create uncertainty that can weigh on the share price.
Market effects
Minimal impact on the broader biotech/clinical‑stage sector; the transaction is company‑specific.
No discernible effect on regional markets.
Limited to investors tracking micro‑cap capital raises.
Counterpoint
The raise could be seen as a sign of cash‑flow stress, suggesting further downside.
Key entities
- CompanyiSpecimen Inc.
Issuer of the Series D convertible preferred stock.
- Placement AgentE.F. Hutton & Co.
Exclusive placement agent for the offering.
